Literature DB >> 9660719

RT in situ PCR for the detection of mRNA transcripts of Fas-L in the immune-privileged placental environment.

A Steele1, D Uckan, P Steele, W Chamizo, K Washington, A Koutsonikolis, R A Good.   

Abstract

Rapid and reproducible detection of RNA in cells and tissue sections is routinely accomplished using in-situ hybridization technique provided that the target number of mRNA copies is above a minimum number. Detection of low copy transcripts is problematic when threshold detection occurs below clear signal resolution or alternatively, when technical problems result in background noise which occludes clear signal. RT in-situ PCR methodology utilizes both the power and specificity of PCR to amplify target whose localization is subsequently detected at the cellular level. RT in-situ PCR methods routinely involve a two-step methodology. mRNA copies are initially transcribed into cDNA. This step is followed by a separate PCR step wherein amplification of the newly synthesized cDNA takes place. A simplified one-step procedure biochemically compartmentalizes these sequential steps within a single applications methodology using the enzyme rTth. This method was successfully applied to detect and localize mRNA transcripts for Fas ligand within the immune privileged placental environment and to provide verification of immunohistochemical localization of gene product.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660719

Source DB:  PubMed          Journal:  Cell Vis        ISSN: 1073-1180


  2 in total

1.  Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction.

Authors:  T E Godfrey; S H Kim; M Chavira; D W Ruff; R S Warren; J W Gray; R H Jensen
Journal:  J Mol Diagn       Date:  2000-05       Impact factor: 5.568

2.  Iris pigment epithelium expressing CD86 (B7-2) directly suppresses T cell activation in vitro via binding to cytotoxic T lymphocyte-associated antigen 4.

Authors:  Sunao Sugita; J Wayne Streilein
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.